YB4P.F · Savara Inc

-

Please sign in to comment on YB4P.F

1 Comment

Admin

4 years ago

Savara Inc is currently in a long term downtrend where the price is trading 1.9% below its 200 day moving average.

From a valuation standpoint, the stock is 58.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 546.6.

Savara Inc's total revenue rose by inf% to $1K since the same quarter in the previous year.

Its net income has increased by 56.7% to $-14M since the same quarter in the previous year.

Finally, its free cash flow fell by 23.6% to $-12M since the same quarter in the previous year.

Based on the above factors, Savara Inc gets an overall score of 3/5.

Sector	Healthcare
Industry	Biotechnology
ISIN	US8051111016
Exchange	F
CurrencyCode	EUR

Market Cap	497M
PE Ratio	None
Target Price	4
Beta	0.52
Dividend Yield	None

ABOUT

Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Langhorne, Pennsylvania.

YB4P.F · Savara Inc

-

Savara Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Savara Inc using a moving average strategy